Skip to main content
Caplight Logo









Combined Therapeutics

Combined Therapeutics

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://www.combinedtx.com/

Last Round

Early Funding

Mar 8, 2023

Total Funding Raised

$500,000

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Combined Therapeutics is a biotechnology company that develops mRNA-based vaccines and therapeutics for infectious diseases and oncology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

mRNA therapeuticsmRNA vaccineslipid nanoparticlesLNPdrug delivery platformtargeted mRNA deliverybiotech platformmolecular adjuvantationdrug discoverybiopharma partnershipmRNA technext-gen vaccinespre-clinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Combined Therapeutics Comparables

Compare Combined Therapeutics with similar companies based on industry and business-model similarity.

Combined Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Strand Therapeutics
81%
aceRNA Technologies Co., Ltd.
81%
Kernal Biologics
81%

Combined Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingMar 8, 2023
GrantSep 25, 2020
SeedDec 12, 2017

Key People

Founding team and executive leadership

Romain Micol

President and co-founder CEO

Founding Team

David Neafus

CFO

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 22, 2026

    Monthly visitors grew 169% MoM, reaching 2.7K.

  • Apr 2, 2026

    Monthly visitors increased 64% MoM.

Combined Therapeutics Filings

Explore SEC and related filing metadata, where available.

Combined Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Combined Therapeutics's valuation, stock price, and market status.

Is Combined Therapeutics a public or private company?

Combined Therapeutics is a private company.

What is the current stock price of Combined Therapeutics?

Combined Therapeutics is a private company with no public stock price. Caplight tracks Combined Therapeutics's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is Combined Therapeutics worth (valuation)?

Valuation information for Combined Therapeutics is not publicly available.

Can I buy Combined Therapeutics stock?

Combined Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Combined Therapeutics's last funding round?

Combined Therapeutics's most recent funding round was Early Funding on March 8, 2023.

Who are the main investors in Combined Therapeutics?

Investor information for Combined Therapeutics is not publicly disclosed.

Will Combined Therapeutics IPO soon?

No public IPO plans have been announced for Combined Therapeutics.

How can I track Combined Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Combined Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range13
Year Founded2016
Last FundingMar 8, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?